1. Scrip
  2. >>Therapy Areas

Genmab Moves On From Darzalex/Tecentriq Failure With Bispecifics Deal

 
• By Jo Shorthouse

Genmab is planning for its post-Darzalex future by exploring bispecific immunotherapies in a collaboration with Immatics that should see it develop immunotherapies directed against three proprietary targets, with the option of two more.

Keys
Genmab may be unlocking the door to its post-Darzalex future

Genmab AS and immatics biotechnologies GMBH have inked a deal to develop multiple bispecific immunotherapies in oncology.

Looking to follow on from success with Darzalex (daratumumab), the Danish biotech is to gain exclusive access to multiple novel...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas